Hola,
Are you new here?

BioProbe-PIT

financed

Local molecular profiling of tumor tissue sections towards personalized immunot...

Local molecular profiling of tumor tissue sections towards personalized immunotherapy Cancer heterogeneity has reinforced the need for personalized treatment modalities. Pre-therapeutic diagnostic testing of heterogeneous tumors helps avoid inefficacious treatments, optimizes targeted therapy, and improves quality... see more

31/07/2018

IBM

150K€

Project Budget: 150K€

Project leader

IBM RESEARCH GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 2 Participantes

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2018-07-31

ERC-PoC-2016: ERC-Proof of Concept-2016 Scope:Objectives

I+D

Cerrada does 9 years

0% 100% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

IBM

150.00K€ | Leader

SP BERNER PLASTIC GROUP

494.99K€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 12 months Date Start: 2017-07-25
End date: 2018-07-31

Project leader

IBM RESEARCH GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 150K€

participation deadline Sin fecha límite de participación.

Project description Cancer heterogeneity has reinforced the need for personalized treatment modalities. Pre-therapeutic diagnostic testing of heterogeneous tumors helps avoid inefficacious treatments, optimizes targeted therapy, and improves quality of life. Within targeted therapy, immunotherapy has led to significant improvements in treatment outcomes and is swiftly being integrated in diagnostic workflows. In this context, routine diagnostic tests currently do not exist, and treatments are further challenged by heterogeneity. Spatially resolved molecular probing of tumors prior to treatment would allow prediction of patient response to immunotherapeutics. We have been developing methods to perform local biochemical reactions at micrometer length scales using nanoliter volumes of biochemicals. These methods are implemented using a scanning probe technology – the microfluidic probe (MFP) – with devices, platforms and assays adapted for application on biological substrates. With this, we are working towards multi-modal molecular profiling of tumors – tissue microprocessing (TMP). Thus far, we have demonstrated TMP for local DNA and mRNA analysis on live cells, for patterning cells and for micro-immunohistochemical tests on tissues. Here, we will leverage TMP concepts to work on the initial steps in pre-commercializing the MFP for diagnostic testing in immunotherapy. Specifically, we aim to (1) develop assays for morphological and molecular analyses of pancreatic tissues using the MFP (2) adapt the assays developed in (1) to be compatible with workflows of state-of-the-art genome and transcriptome analysis for molecular profiling of tumors in diagnostics (3) validate these techniques for patient samples. With this PoC grant, we envision to translate the MFP technology from the lab to the clinic for personalized immunotherapy.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers